To investigate non-inferiority of intermittent docetaxel compared to continuous docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).
Introduction
Androgen-deprivation therapy (ADT), the primary treatment for hormone-sensitive metastatic prostate cancer, delays clinical progression and development of symptoms in patients [1, 2] . Failure of ADT, leading to castration-resistant disease, occurs after~18 months [3] [4] [5] . Until the approval of abiraterone and enzalutamide in the pre-docetaxel setting, 3-weekly docetaxel plus prednisone was the sole first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) [6] [7] [8] [9] . The TAX 327 study showed an overall survival (OS) benefit of 3-weekly docetaxel over mitoxantrone of 2.9 months (19.2 vs 16.3 months), whilst weekly docetaxel was widely used because of better toxicity and tolerability despite not having a significant OS benefit [10] . In the CALGB 90401 trial, the median OS of docetaxel alone was 21.5 months, exceeding the OS of 19.2 months reported for the TAX 327 study [11] . Despite the introduction of new agents, such as abiraterone, enzalutamide, sipuleucel-T or radium-223, docetaxel remains an essential therapeutic option for patients with CRPC [12] [13] [14] [15] . Especially the recently published data on the impact of docetaxel combined with ADT in men with high-volume metastatic prostate cancer in the first-line setting has led to its revival [16] [17] [18] . One of the major concerns of docetaxel-based therapy with respect to clinical outcome is the frequent discontinuation of therapy due to cumulative toxicities [19, 20] . Compared with standard continuous docetaxel therapy, intermittent docetaxel therapy may have a favourable toxicity profile. Intermittent docetaxel therapy is based on a limited number of chemotherapy cycles until disease stabilisation is seen; upon progression (progression of PSA and/or clinical progression) treatment is re-administered [21] [22] [23] [24] [25] . A phase II trial in patients with CRPR with second-and third-line treatment showed that intermittent docetaxel and estramustine therapy was well tolerated with excellent clinical response rates [21] .
The aim of the present study was to investigate patient safety and prove non-inferiority of intermittent docetaxel treatment compared to continuous docetaxel administration in a phase III multicentre trial of patients with mCRPC (PRINCE study).
Patients and Methods

Patients
This investigator-initiated, randomised, open phase III study was performed in 44 German uro-oncological centres. Eligibility required histologically confirmed mCRPC as defined by the guidelines of the European Association of Urology [14] . Other criteria included Karnofsky score of ≥60%, adequate bone marrow and sufficient hepatic, renal and cardiac function (see supplemental study protocol for full list of inclusion/exclusion criteria Data S1). All patients gave written informed consent. The study was approved by the respective institutional review boards in accordance with the Declaration of Helsinki.
Randomisation and Treatment
Patients were randomised (1:1) to either standard therapy arm with continuous docetaxel or to the intermittent docetaxel arm. In both arms patients received either weekly docetaxel (35 mg/m 2 on days 1, 8, 15, repeat cycle at day 29) or 3-weekly docetaxel (75 mg/m 2 on day 1 every 21 days) as previously described [10] . The dosing regimen (weekly/3-weekly) was decided by the treating investigator and no changes between dosing regimens were allowed. The study sequence consisted of three cycles for weekly docetaxel or four cycles for 3-weekly docetaxel. Dexamethasone was administered as follows: 8 mg i.v. 30 min before docetaxel application; oral 8 mg 12 h before and after the weekly docetaxel application; oral 8 mg 12 h before and 12, 24, 36 h after the 3-weekly application. In the intermittent docetaxel arm, docetaxel was given for one study sequence of 12 weeks and then paused until clinical disease progression. Before each docetaxel application predefined laboratory criteria had to be met (see Data S1), otherwise treatment was postponed for 1 week or, if application was not possible after 2 weeks, docetaxel was discontinued.
A dose reduction (30 mg/m 2 weekly, 60 mg/m 2 3-weekly) was determined for patients with a neutrophil count of <0.5 9 10 9 /L for >7 days, febrile neutropaenia, a platelet count of <25 9 10 9 /L or bleeding related to low platelet count. Prophylactic treatment with granulocyte colony-stimulating factor was permitted.
Complete blood count, assessment of toxicities and pain scale measures were repeated at weekly intervals. Before every chemotherapy cycle, a clinical examination and complete laboratory assessment were performed. After one study sequence or three cycles (weekly schedule) or four cycles (3-weekly schedule) clinical and radiological examinations were performed (see Data S1). During the therapy-free interval of the intermittent docetaxel arm clinical, radiological and laboratory examinations were repeated monthly. Adverse events (AEs) were classified according to the Common Toxicity Criteria of the National Cancer Institute (CTCAE) version 3.0.
Follow-up and Outcome
Progression was defined by the presence of at least one of the following criteria: increased serum PSA level of >4 ng/mL with a minimum of 50% over baseline level (confirmed in two consecutive measurements; for the intermittent docetaxel arm the PSA baseline referred to the PSA nadir after continuing docetaxel); radiological progression (according to Response Evaluation Criteria In Solid Tumors [RECIST]); symptomatic progression with aggravated tumour associated pain. Response was determined by serum PSA level, symptomatic response (pain), and according to RECIST criteria (see Data S1).
Study Objectives
The aim of the study was to demonstrate non-inferiority of intermittent docetaxel therapy compared to the standard continuous docetaxel therapy with 1-year survival rates as the primary endpoint. Secondary endpoints were: median OS, progression-free survival (PFS), median time to treatment failure (TTF), and toxicity.
Statistical Analysis
In the study protocol from the year 2005, a difference of 12.5% in 1-year survival was defined as non-inferiority margin (d = À0.125) for the comparison of intermittent and continuous docetaxel therapy. It was expected to include a total of 424 patients (247 events) to achieve 80% power at the one-sided 2.5% significance level. The planned recruitment period was 24 months and the minimum follow-up interval was 18 months. The primary hypothesis was tested using a two-sided 95% CI. However, to facilitate comparison of our data to other current studies investigating similar scientific issues, additionally (post hoc) a non-inferiority margin for the hazard ratio (HR) of OS was assumed to be 1.25 and data were analysed using the Cox proportional hazard model using the one-sided CI for the HR. Descriptive analyses included median and ranges for continuous variables, absolute and percentage frequencies for categorical variables. Chi-squared tests (categorical variables, trend test if ordinal), MannWhitney tests (continuous variables), log-rank tests based on Kaplan-Meier estimators and Cox proportional hazard regression (censored data) were used for comparisons of study arms. All these analyses are secondary and thus not confirmatory except for the primary analysis. P values for baseline comparisons are given but these should not be interpreted as confirmatory.
Results
Patient Characteristics and Treatment
Between August 2005 and May 2008, a total of 187 patients were randomised, of which 31 (16.5%) were ineligible for treatment. Thus, the intention-to-treat analysis included 156 patients (78 per study arm) with 91 events ( Fig S1 shows the Consolidated Standards of Reporting Trials (CONSORT) diagram of the study). This reduced the statistical power of the analysis to 39%.
Baseline characteristics were comparable between treatment arms ( Table 1 ). The median age was 69 years and 47% of patients were aged ≥70 years. The median time interval from primary diagnosis of prostate cancer to study inclusion was comparable in both arms (intermittent docetaxel: 44 months; continuous docetaxel: 56.5 months; P = 0.31). The median PSA level at study entry was balanced between the two study arms (intermittent docetaxel: 80 ng/mL; continuous docetaxel: 64 ng/mL; P = 0.85).
The follow-up period was extended in order to collect data for the post hoc OS analysis. The median follow-up (intermittent docetaxel: 26.8 months; continuous docetaxel: 33.8 months) and the median number of cycles (intermittent docetaxel: 5.5 cycles; continuous docetaxel: 5.5 cycles; P = 0.647) were comparable. The median (range) treatment duration was 118 (1-947) days in the intermittent docetaxel arm vs 109 (1-609) days in the continuous docetaxel arm (P = 0.27). In the intermittent docetaxel arm, 37 patients (47%) received more than one treatment sequence. For these patients the median (range) treatment duration was 264 (104-947) days. The median (range) length of a treatment holiday in the intermittent docetaxel arm was 110 (13-486) days, which represented 38% of the overall treatment duration. The median (range) duration of the first treatment holiday was 83 (13-207) days; the distribution is shown in Table 2 .
Efficacy: Primary Non-inferiority Analysis
The 1-year survival was 78% (95% CI: 67, 88) in the intermittent docetaxel arm vs 75% (95% CI: 64, 85) in the continuous docetaxel arm. The result for the 1-year survival showed that intermittent docetaxel therapy was non-inferior Fig. 3 ). The clinical response measured by RECIST criteria, the pain response, and PSA response, as well as the combination of the response criteria was comparable in both treatment arms (Table 3) .
AEs
There was no statistically significant difference in the rate of AEs between the intermittent docetaxel and continuous docetaxel regimen (see Table S1 for haematological and non-haematological AEs). A total of 38 patients (49%) in the intermittent docetaxel and 36 patients (46%) in the continuous docetaxel arm withdrew from treatment (P = 0.325). Reasons included AEs (11 patients, 14.5%), patient will (20, 26.3%) or 'other' (7, 9.2%) in the intermittent Presents the time until the initiation of the second sequence. 
Subsequent Treatments
Overall, 55 men received further treatments that were administered during the follow-up period after exiting the PRINCE study. The number of treatments and a detailed summary of the agents are shown in Table 4 according to each treatment arm.
Discussion
PRINCE presents the only randomised phase III trial investigating the efficacy of intermittent vs continuous docetaxel therapy, 3-weekly or weekly, for patients with mCRPC. The 1-year survival showed non-inferiority for intermittent docetaxel and thus the primary objective of the study was reached. Non-inferiority in median OS could not be proven for intermittent docetaxel. The median OS was determined post hoc and it remains unclear, if a larger sample size could have changed the result. The difference in PFS between the study arms was not significant. Data on intermittent vs continuous docetaxel treatment is limited. The efficacy of an intermittent docetaxel therapy or docetaxel rechallenge has been tested in a few retrospective studies and in one prospective one-armed study with a historical control group [25] [26] [27] [28] . These studies observed median OS of 15.8-19 months for intermittent docetaxel, corresponding well to the OS seen in the present study, with one exception where a median OS of 13 months was stated [25] , probably due to higher age of enrolled patients [26] [27] [28] . The median OS in the intermittent docetaxel arm of the PRINCE-study is comparable to the one that Oudard et al. [26] derived from retrospective data of 223 patients that were re-challenged with docetaxel after a good initial response (18.2 months). In a prospective study by Li et al. [27] there was no significant A rationale for the intermittent treatment is to achieve comparable disease control with a lower cumulative chemotherapy dose and consequently less toxicity and an improvement in quality of life (QoL). The results of the present study support this assumption only partially. Intermittent therapy saved 17% of cumulative docetaxel exposure. Nonetheless, haematological AEs were comparable in both groups. The rate of Grade 3 or 4 neutropaenia was 8.9% in both study arms. QoL was not assessed in the present study, but based on the results reported by Li et al. [27] it can be hypothesised that intermittent docetaxel therapy improves QoL at least for some parameters. Patients receiving intermittent docetaxel had a median (range) treatment holiday of 110 (13-486) days, comprising 38% of the overall treatment duration. This is comparable to the median duration of the first treatment holidays found in other studies: 18 weeks (range 4-70) for patients in the Androgenindependent prostate cancer Study of Calcitriol ENhancing Taxotere (ASCENT) trial who received intermittent docetaxel plus either calcitriol or placebo (45/250 patients) [29] and 5.3 months (range 2-20) reported by Li et al. [27] , which dropped to 2.8 months (range 1-7) in the second holiday; 67% of patients (28/42) with intermittent treatment reached the first docetaxel holiday and the therapy was well tolerated.
Overall, one-third of men in this trial received subsequent therapies after exiting the PRINCE study. Most of these men were re-challenged with docetaxel and none of these men received cabazitaxel or advanced anti-androgen agents, as these agents were not available at that time point.
This investigator-initiated study is limited by the fact that the planned number of patients could not be recruited. This also influenced the postponed finalisation of the data and preparation of the manuscript. There were no further confounders leading to a delayed publication of the data. Further, the results of the non-inferiority analysis for 1-year survival might be affected by a rather large number of withdrawals. The doubled PFS of the patients receiving intermittent docetaxel may be influenced by the different definitions of PSA progression in each treatment arm.
Despite the limitations of our present study and taking the published data into account, intermittent docetaxel treatment is well tolerated and has the potential to achieve comparable efficacy. This might be particularly interesting with regard to the positive results of the ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) and the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) studies, which have led to a wider indication for docetaxel-based therapy. In both studies, docetaxel was prescribed to patients with hormonesensitive metastatic prostate cancer and showed an increase in OS compared with ADT alone [16] [17] [18] . The STAMPEDE trial is an adaptive multi-arm, multi-stage study design comparing various treatment arms (initial agents: bisphosphonate, zoledronic acid, docetaxel and celecoxib alone and/or in combination) to one control arm with the standard of care [18, 30] . At the outset of the trial the standard of care was ADT and was changed to ADT plus docetaxel after publication of James et al. [31] in 2017 and novel agents are continuously added. The future results of the control arm will also be of great interest in regard to subsequent therapies, especially after the update in standard of care, as results for the initial control arm receiving ADT were also published [32] . Overall, the results of the STAMPEDE and CHAARTED trials highlight the importance of docetaxel in the ongoing discussion about treatment options for metastatic prostate cancer. With the lack of a survival benefit of the weekly docetaxel regimen in the TAX 327 study, the 3-weekly docetaxel regimen presents the current standard administered in the hormone-sensitive setting as in the STAMPEDE and CHAARTED, and is the standard in our centre (Charit e University Medicine Berlin) and most centres for mCRPC [10, 17, 32] . Based on the data of the present trial, the initiating hospital currently offers men with mCRPC and an indication for docetaxel an intermittent therapy.
Conclusion
The initial hypothesis of PRINCE was to show that an intermittent docetaxel-based chemotherapy is non-inferior to a continuous therapy. The results of this trial regarding 1-year survival support this hypothesis with reservations, which have to be interpreted cautiously due to the fact that the trial did not reach full recruitment.
